Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 2 July 2021

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods in Australia, aiming to ensure that such goods are of acceptable quality, safety, and efficacy. This Act addresses the problem of maintaining public health and safety by controlling the quality and supply of therapeutic goods, which includes medicines, medical devices, and other related products. The enacting body responsible for this legislation is the Commonwealth Parliament, with the objective of safeguarding the health and safety of the Australian population by ensuring that therapeutic goods are properly regulated and monitored. This Act allows the Therapeutic Goods Administration to suspend licences for the manufacture of therapeutic goods if certain conditions are not met, as a means of enforcing compliance with the regulatory standards set out in the Act. In the context of the Therapeutic Goods Act 1989, the publication of a list of manufacturers whose licences have been suspended for the manufacture of therapeutic goods serves to inform the public and industry stakeholders about any significant regulatory actions taken by the Therapeutic Goods Administration. The example provided in the gazette indicates that the licences of two companies, Veolia Environmental Services (Australia) Pty Ltd and Royal Adelaide Hospital Radiopharmacy, have been suspended at the request of the manufacturers themselves, with the suspensions set to last until specific future dates. This action underscores the administration's commitment to enforcing the Act's provisions to maintain the integrity and safety of the therapeutic goods market in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to all therapeutic goods manufactured, supplied, advertised, or evaluated within Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. This legislation extends to all entities involved in the manufacturing, importation, supply, and advertising of therapeutic goods, with specific provisions for different categories of therapeutic goods. The Act is a Commonwealth law, thereby having national jurisdiction across all states and territories in Australia. It includes various exclusions and exemptions, such as those for goods used for personal, non-commercial purposes or for research and clinical trials under certain conditions. The scope of the Act can be further extended or restricted through subordinate instruments such as regulations and legislative instruments, which provide detailed specifications and operational guidelines for the administration and enforcement of the Act. These regulations can address specific aspects of therapeutic goods, including quality, safety, efficacy, and post-market surveillance.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) establishes a regulatory framework for the manufacturing, importation, advertising, and distribution of therapeutic goods in Australia. Section 41(1)(d) of the Act empowers the Secretary to suspend a manufacturer's licence for the production of therapeutic goods under specific conditions. This recent publication under Section 41 details the suspension of licences for two entities: Veolia Environmental Services (Australia) Pty Ltd, with Licence No. 83579, and Royal Adelaide Hospital Radiopharmacy, with Licence No. MI-12112004-LI-000163-1. Both suspensions are effective from 28 June 2019 to 28 June 2022 and 30 June 2022, respectively, and were requested by the manufacturers themselves. Under the Act, the Secretary must notify the public of such licence suspensions to ensure transparency and accountability in the therapeutic goods industry. The obligations imposed on the entities whose licences are suspended include ceasing all manufacturing activities related to the therapeutic goods within the specified timeframes. Additionally, these entities are required to comply with any other conditions or directions provided by the Secretary during the suspension period. Failure to comply with the terms of a licence suspension may result in legal consequences. The Act does not explicitly outline offences or penalties for breaching suspension orders in this context; however, broader provisions within the Act may apply. For example, general contraventions of the Act could lead to fines, imprisonment, or both, depending on the severity of the breach. The specific maximum penalties would be determined by the courts based on the nature and circumstances of the offence. In addition to potential criminal penalties, the entities involved may face civil liabilities. These can include compensation claims for any harm caused by non-compliance, as well as administrative actions that could further impede their operations. It is crucial for the entities to adhere strictly to the terms of the suspension to avoid any adverse legal consequences. The publication of the suspension details serves as an official notification to the public and industry stakeholders, ensuring that all parties are aware of the regulatory status of these manufacturers. This transparency helps maintain the integrity of the therapeutic goods market and protects public health by ensuring that only compliant entities are permitted to manufacture therapeutic goods.